Dr. McKay Discusses Combinations in Renal Cell Carcinoma

Video

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses combinations in renal cell carcinoma.

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses combinations in renal cell carcinoma (RCC).

Monotherapy with VEGF-targeted agents and immunotherapy has been the mainstay of RCC treatment over the last decade, but recent data with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) has provided an argument in favor of combinations.

Looking ahead, McKay says that the next 5 to 10 years will see more combinations coming into the frontline setting to improve response rates and durability of response for patients.

With such a rapidly-changing treatment landscape, McKay says that it is important for community providers to learn how to manage toxicities, especially the immune-related adverse events associated with combination immunotherapy. As chemotherapy is phased out and the field becomes more reliant on targeted therapies and immunotherapies, learning how to administer different novel drugs will be important moving forward, McKay concludes.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,